Suven Life Sciences Limited has informed the Exchange regarding a press release dated April 15, 2024, titled ""Suven Life Sciences to present Phase-2 Positive Results on Samelisant (SUVN-G3031) at American Academy of Neurology (AAN) 2024 Annual Meeting, Denver, USA"".